Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
This study, called PROACT 3, is looking at whether telling people their risk for coronary artery disease (CAD) based on their genes (called a polygenic risk score or PRS) changes their heart health. We want to see if knowing this information helps people make lifestyle changes. You could join if you are 30-75 years old, receive primary care at Mass General Brigham, and are not currently taking cholesterol-lowering medicines. All 500 participants will have their CAD PRS tested. Some will get their results right away, while others will get them after 12 months. The main goal is to see how your "bad" cholesterol (LDL-C) changes over 12 months.
- Study design
- This is a randomized study with 500 participants. You would be randomly assigned to one of two groups: immediate disclosure of your genetic risk score or deferred disclosure.
- What's involved
- You would have your CAD PRS tested. The study will track changes in your cholesterol and other health measures over 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months, with the primary outcome measured at the end of this period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Change in low-density lipoprotein cholesterol (LDL-C) from baseline to 12 months12 months
The primary outcome is the change in low-density lipoprotein cholesterol (LDL-C) from baseline to 12 months. LDL-C values will be obtained from clinical measurements recorded in the electronic health record. The analysis will compare the change in LDL-C between participants randomized to immediate disclosure versus deferred disclosure of CAD PRS results.